Clover Health Investments Overview
Latest ROE for Clover Health Investments: -4.88% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-4.88%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CLOV is -4.88%. That is below the Finance sector average of 16.73%. Investors often review this figure alongside Clover Health Investments's historical trend and sector peers before judging valuation or financial health.
Against Finance companies, CLOV currently prints -4.88% for ROE, while the sector average sits near 16.73%. That is roughly 129.2% below the sector mean. Large gaps often invite a closer look at Clover Health Investments's growth, margins, and balance sheet.
Return on Equity shows how effectively Clover Health Investments converts resources into returns. At -4.88%, CLOV may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CLOV's ROE (-4.88%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Clover Health Investments's ROE against similar Finance names. You can also browse sector and industry screens on Stockcircle for a broader set of Finance companies and their key multiples and fundamentals.
